Atjaunināt sīkdatņu piekrišanu

Multifaceted Roles of Crystallography in Modern Drug Discovery [Mīkstie vāki]

Edited by , Edited by , Edited by
  • Formāts: Paperback / softback, 240 pages, height x width: 235x155 mm, weight: 3869 g, 89 Illustrations, color; 18 Illustrations, black and white; XI, 240 p. 107 illus., 89 illus. in color., 1 Paperback / softback
  • Sērija : NATO Science for Peace and Security Series A: Chemistry and Biology
  • Izdošanas datums: 12-Mar-2015
  • Izdevniecība: Springer
  • ISBN-10: 9401797242
  • ISBN-13: 9789401797245
  • Mīkstie vāki
  • Cena: 91,53 €*
  • * ši ir gala cena, t.i., netiek piemērotas nekādas papildus atlaides
  • Standarta cena: 107,69 €
  • Ietaupiet 15%
  • Grāmatu piegādes laiks ir 3-4 nedēļas, ja grāmata ir uz vietas izdevniecības noliktavā. Ja izdevējam nepieciešams publicēt jaunu tirāžu, grāmatas piegāde var aizkavēties.
  • Daudzums:
  • Ielikt grozā
  • Piegādes laiks - 4-6 nedēļas
  • Pievienot vēlmju sarakstam
  • Formāts: Paperback / softback, 240 pages, height x width: 235x155 mm, weight: 3869 g, 89 Illustrations, color; 18 Illustrations, black and white; XI, 240 p. 107 illus., 89 illus. in color., 1 Paperback / softback
  • Sērija : NATO Science for Peace and Security Series A: Chemistry and Biology
  • Izdošanas datums: 12-Mar-2015
  • Izdevniecība: Springer
  • ISBN-10: 9401797242
  • ISBN-13: 9789401797245

The present work offers a snapshot of the state-of-the-art of crystallographic, analytical, and computational methods used in modern drug design and development. Topics discussed include: drug design against complex systems (membrane proteins, cell surface receptors, epigenetic targets, and ribosomes); modulation of protein-protein interactions; the impact of small molecule structures in drug discovery and the application of concepts such as molecular geometry, conformation, and flexibility to drug design; methodologies for understanding and characterizing protein states and protein-ligand interactions during the drug design process; and monoclonal antibody therapies. These methods are illustrated through their application to problems of medical and biological significance, such as viral and bacterial infections, diabetes, autoimmune disease, and CNS diseases. As approaches to drug discovery have changed over time, so have the methodologies used to solve the varied, new, and difficult problems encountered in drug discovery. In recent years we have seen great progress in the fields of genetics, biology, chemistry, and medicine, but there are still many unmet medical needs, from bacterial infections to cancer to chronic maladies, that require novel, different, or better therapies. This work will be of interest to researchers and policy makers interested in the latest developments in drug design.

1 Engineering G Protein-Coupled Receptors for Drug Design
1(18)
Miles Congreve
Andrew S. Dore
Ali Jazayeri
Rebecca Nonoo
2 Structural Insights into Activation and Allosteric Modulation of G Protein-Coupled Receptors
19(8)
Andrew C. Kruse
3 Epigenetic Drug Discovery
27(14)
Chun-Wa Chung
4 Crystallography and Biopharmaceuticals
41(12)
Richard Pauptit
5 Structural Chemistry and Molecular Modeling in the Design of DPP4 Inhibitors
53(16)
Giovanna Scapin
6 Considerations for Structure-Based Drug Design Targeting HIV-1 Reverse Transcriptase
69(14)
Eddy Arnold
Sergio E. Martinez
Joseph D. Bauman
Kalyan Das
7 Protein-Ligand Interactions as the Basis for Drug Action
83(10)
Gerhard Klebe
8 The Protein Data Bank: Overview and Tools for Drug Discovery
93(14)
Helen M. Berman
Peter W. Rose
Shuchismita Dutta
Christine Zardecki
Andreas Prlic
9 Small Molecule Crystal Structures in Drug Discovery
107(8)
Colin Groom
10 Protein Aggregation and Its Prediction
115(14)
Ricardo Grana-Montes
Salvador Ventura
11 Importance of Protonation States for the Binding of Ligands to Pharmaceutical Targets
129(12)
Alberto Podjarny
Eduardo Howard
12 Protein-Protein Interactions: Structures and Druggability
141(24)
David B. Ascher
Harry C. Jubb
Douglas E.V. Pires
Takashi Ochi
Alicia Higueruelo
Tom L. Blundell
13 Achieving High Quality Ligand Chemistry in Protein-Ligand Crystal Structures for Drug Design
165(18)
Oliver S. Smart
Gerard Bricogne
14 Molecular Obesity, Potency and Other Addictions in Drug Discovery
183(14)
Michael M. Hann
15 Adventures in Small Molecule Fragment Screening by X-ray Crystallography
197(12)
Joseph D. Bauman
Disha Patel
Eddy Arnold
16 Structure-Based Drug Design to Perturb Function of a tRNA-Modifying Enzyme by Active Site and Protein-Protein Interface Inhibition
209(14)
Gerhard Klebe
17 Molecular Interaction Analysis for Discovery of Drugs Targeting Enzymes and for Resolving Biological Function
223
U. Helena Danielson